M-CSF attenuates severity of chronic GVHD after unrelated BMT

F. Kimura, K. Sato, H. Akiyama, H. Sao, Shinichiro Okamoto, N. Kobayashi, M. Hara, K. Kawa, K. Motoyoshi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

To study the effects of M-CSF administration on long-term outcomes of unrelated BMT, we retrospectively analyzed data from patients transplanted through the Japan Marrow Donor Program. We obtained data from 54 patients who received M-CSF just after BMT and 500 patients who did not receive M-CSF or G-CSF acted as controls. There were no significant differences between the two cohorts with respect to OS, acute GVHD or relapse. Although the incidence of chronic GVHD was comparable between the two groups, extensive chronic GVHD was observed significantly less often in the M-CSF cohort than in the control group. Multivariate analysis identified M-CSF as a significant factor for attenuating extensive chronic GVHD (relative risk: 0.73; 95% confidence interval: 0.55-0.94; P=0.012). We also found the same results in matched-pair analysis. Our observation suggests the potential for clinical use of M-CSF to dampen severe chronic GVHD.

Original languageEnglish
Pages (from-to)426-429
Number of pages4
JournalBone Marrow Transplantation
Volume47
Issue number3
DOIs
Publication statusPublished - 2012 Jan 1

Fingerprint

Macrophage Colony-Stimulating Factor
Matched-Pair Analysis
Granulocyte Colony-Stimulating Factor
Japan
Multivariate Analysis
Bone Marrow
Observation
Tissue Donors
Confidence Intervals
Recurrence
Control Groups
Incidence

Keywords

  • chronic GVHD
  • M-CSF
  • unrelated BMT

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Kimura, F., Sato, K., Akiyama, H., Sao, H., Okamoto, S., Kobayashi, N., ... Motoyoshi, K. (2012). M-CSF attenuates severity of chronic GVHD after unrelated BMT. Bone Marrow Transplantation, 47(3), 426-429. https://doi.org/10.1038/bmt.2011.90

M-CSF attenuates severity of chronic GVHD after unrelated BMT. / Kimura, F.; Sato, K.; Akiyama, H.; Sao, H.; Okamoto, Shinichiro; Kobayashi, N.; Hara, M.; Kawa, K.; Motoyoshi, K.

In: Bone Marrow Transplantation, Vol. 47, No. 3, 01.01.2012, p. 426-429.

Research output: Contribution to journalArticle

Kimura, F, Sato, K, Akiyama, H, Sao, H, Okamoto, S, Kobayashi, N, Hara, M, Kawa, K & Motoyoshi, K 2012, 'M-CSF attenuates severity of chronic GVHD after unrelated BMT', Bone Marrow Transplantation, vol. 47, no. 3, pp. 426-429. https://doi.org/10.1038/bmt.2011.90
Kimura, F. ; Sato, K. ; Akiyama, H. ; Sao, H. ; Okamoto, Shinichiro ; Kobayashi, N. ; Hara, M. ; Kawa, K. ; Motoyoshi, K. / M-CSF attenuates severity of chronic GVHD after unrelated BMT. In: Bone Marrow Transplantation. 2012 ; Vol. 47, No. 3. pp. 426-429.
@article{fefb3855c9754a43b9258f09a6c5ad98,
title = "M-CSF attenuates severity of chronic GVHD after unrelated BMT",
abstract = "To study the effects of M-CSF administration on long-term outcomes of unrelated BMT, we retrospectively analyzed data from patients transplanted through the Japan Marrow Donor Program. We obtained data from 54 patients who received M-CSF just after BMT and 500 patients who did not receive M-CSF or G-CSF acted as controls. There were no significant differences between the two cohorts with respect to OS, acute GVHD or relapse. Although the incidence of chronic GVHD was comparable between the two groups, extensive chronic GVHD was observed significantly less often in the M-CSF cohort than in the control group. Multivariate analysis identified M-CSF as a significant factor for attenuating extensive chronic GVHD (relative risk: 0.73; 95{\%} confidence interval: 0.55-0.94; P=0.012). We also found the same results in matched-pair analysis. Our observation suggests the potential for clinical use of M-CSF to dampen severe chronic GVHD.",
keywords = "chronic GVHD, M-CSF, unrelated BMT",
author = "F. Kimura and K. Sato and H. Akiyama and H. Sao and Shinichiro Okamoto and N. Kobayashi and M. Hara and K. Kawa and K. Motoyoshi",
year = "2012",
month = "1",
day = "1",
doi = "10.1038/bmt.2011.90",
language = "English",
volume = "47",
pages = "426--429",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - M-CSF attenuates severity of chronic GVHD after unrelated BMT

AU - Kimura, F.

AU - Sato, K.

AU - Akiyama, H.

AU - Sao, H.

AU - Okamoto, Shinichiro

AU - Kobayashi, N.

AU - Hara, M.

AU - Kawa, K.

AU - Motoyoshi, K.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - To study the effects of M-CSF administration on long-term outcomes of unrelated BMT, we retrospectively analyzed data from patients transplanted through the Japan Marrow Donor Program. We obtained data from 54 patients who received M-CSF just after BMT and 500 patients who did not receive M-CSF or G-CSF acted as controls. There were no significant differences between the two cohorts with respect to OS, acute GVHD or relapse. Although the incidence of chronic GVHD was comparable between the two groups, extensive chronic GVHD was observed significantly less often in the M-CSF cohort than in the control group. Multivariate analysis identified M-CSF as a significant factor for attenuating extensive chronic GVHD (relative risk: 0.73; 95% confidence interval: 0.55-0.94; P=0.012). We also found the same results in matched-pair analysis. Our observation suggests the potential for clinical use of M-CSF to dampen severe chronic GVHD.

AB - To study the effects of M-CSF administration on long-term outcomes of unrelated BMT, we retrospectively analyzed data from patients transplanted through the Japan Marrow Donor Program. We obtained data from 54 patients who received M-CSF just after BMT and 500 patients who did not receive M-CSF or G-CSF acted as controls. There were no significant differences between the two cohorts with respect to OS, acute GVHD or relapse. Although the incidence of chronic GVHD was comparable between the two groups, extensive chronic GVHD was observed significantly less often in the M-CSF cohort than in the control group. Multivariate analysis identified M-CSF as a significant factor for attenuating extensive chronic GVHD (relative risk: 0.73; 95% confidence interval: 0.55-0.94; P=0.012). We also found the same results in matched-pair analysis. Our observation suggests the potential for clinical use of M-CSF to dampen severe chronic GVHD.

KW - chronic GVHD

KW - M-CSF

KW - unrelated BMT

UR - http://www.scopus.com/inward/record.url?scp=85027925804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027925804&partnerID=8YFLogxK

U2 - 10.1038/bmt.2011.90

DO - 10.1038/bmt.2011.90

M3 - Article

AN - SCOPUS:85027925804

VL - 47

SP - 426

EP - 429

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -